Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms

British Journal of Clinical Pharmacology
Gavin P ReynoldsCaroline F Dalton

Abstract

The treatment of severe mental illness, and of psychiatric disorders in general, is limited in its efficacy and tolerability. There appear to be substantial interindividual differences in response to psychiatric drug treatments that are generally far greater than the differences between individual drugs; likewise, the occurrence of adverse effects also varies profoundly between individuals. These differences are thought to reflect, at least in part, genetic variability. The action of psychiatric drugs primarily involves effects on synaptic neurotransmission; the genes for neurotransmitter receptors and transporters have provided strong candidates in pharmacogenetic research in psychiatry. This paper reviews some aspects of the pharmacogenetics of neurotransmitter receptors and transporters in the treatment of psychiatric disorders. A focus on serotonin, catecholamines and amino acid transmitter systems reflects the direction of research efforts, while relevant results from some genome-wide association studies are also presented. There are many inconsistencies, particularly between candidate gene and genome-wide association studies. However, some consistency is seen in candidate gene studies supporting established pharmacologica...Continue Reading

References

Jun 1, 1996·Journal of Neurochemistry·A HeilsK P Lesch
Jan 26, 2000·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·J ScharfetterH N Aschauer
Feb 23, 2000·Neuroreport·D K KimB J Carroll
Oct 12, 2000·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·B G PollockD J Kupfer
Feb 13, 2001·Trends in Pharmacological Sciences·D Pickar, K Rubinow
Jun 14, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Bernard LererFabio Macciardi
Aug 31, 2002·The American Journal of Psychiatry·Hsien-Yuan LaneWen-Ho Chang
Dec 19, 2003·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·György SzekeresZoltán Janka
Apr 3, 2004·American Journal of Pharmacogenomics : Genomics-related Research in Drug Development and Clinical Practice·Tatiana RomanMara Helena Hutz
Apr 6, 2004·Controlled Clinical Trials·A John RushUNKNOWN STAR*D Investigators Group
Aug 3, 2004·The British Journal of Psychiatry : the Journal of Mental Science·Ross McD YoungErnest P Noble
Sep 1, 2004·The American Journal of Psychiatry·Keizo YoshidaCharles B Nemeroff
Sep 15, 2004·Biological Psychiatry·Michael J ParsonsAndrew J Makoff
Sep 28, 2004·The International Journal of Neuropsychopharmacology·Sylvie LemondePaul R Albert
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Nov 10, 2005·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Rudi HwangJames L Kennedy
Nov 18, 2005·Brain Research. Cognitive Brain Research·Michael X CohenCharan Ranganath
Apr 28, 2006·American Journal of Human Genetics·Francis J McMahonHusseini Manji
Apr 28, 2006·American Journal of Human Genetics·Xian-Zhang HuDavid Goldman

❮ Previous
Next ❯

Citations

Sep 16, 2015·Psychological Medicine·E Appiah-KusiS Bhattacharyya
Feb 20, 2014·British Journal of Clinical Pharmacology·Ann K Daly, Ingolf Cascorbi
Jun 18, 2015·Pharmacogenomics·Daniela Caldirola, Giampaolo Perna
Sep 6, 2014·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Claudio TerranovaSanto Davide Ferrara
Feb 18, 2015·Epigenomics·Christina A CastellaniShiva M Singh
Oct 4, 2016·European Archives of Psychiatry and Clinical Neuroscience·Michael PaulzenGeorgios Schoretsanitis
Nov 28, 2017·Pharmacogenomics·Stefano FortinguerraPietro Giusti
Jan 11, 2018·Therapeutic Advances in Drug Safety·Rashmi R Shah, Andrea Gaedigk
Sep 12, 2017·Journal of Psychopharmacology·Gavin P Reynolds, Olga O McGowan
Aug 22, 2018·Journal of Psychiatric and Mental Health Nursing·Erin MuladoreBarbara Kupferschmid
Jun 9, 2016·Journal of Clinical Psychopharmacology·Jose de Leon
May 12, 2018·European Journal of Clinical Pharmacology·Peipei WangWeimin Cai
Apr 16, 2019·The British Journal of Radiology·Sue Y YiJohn-Paul J Yu
Feb 6, 2017·Clinical and Translational Science·M L RizkK E Dooley
Dec 27, 2019·Current Drug Research Reviews·Nobue KitanakaJunichi Kitanaka
Mar 8, 2016·The Mental Health Clinician·Jonathan F Lister

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Handbook of Experimental Pharmacology
Gavin P Reynolds
American Journal of Pharmacogenomics : Genomics-related Research in Drug Development and Clinical Practice
M J ArranzR W Kerwin
© 2021 Meta ULC. All rights reserved